ARCA biopharma Financials

$18.8 M

Mkt cap, 16-Feb-2018
Net income (Q1, 2017)(4.3 M)
Cash, 31-Mar-20176.2 M

Market Value

Revenue/Financials

Income Statement

Annual

USDFY, 2016

Net Income

(16.4 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

1.4 m1.3 m

General and administrative expense

1 m950 k

Operating expense total

2.4 m2.3 m

EBIT

(2.4 m)(2.3 m)

Pre tax profit

(2.4 m)(2.3 m)

Net Income

(4.8 m)(7.1 m)(2.7 m)(5.5 m)(8.3 m)(3.6 m)(7.5 m)(12.2 m)(4.3 m)

Balance Sheet

Annual

USDFY, 2016

Cash

7.4 m

Current Assets

21.4 m

PP&E

66 k

Total Assets

24.6 m

Accounts Payable

1.2 m

Current Liabilities

2.4 m

Total Liabilities

2.4 m

Additional Paid-in Capital

134.7 m

Retained Earnings

(112.5 m)

Total Equity

22.2 m

Financial Leverage

1.1 x

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

19.4 m17.2 m12.2 m44.1 m41.5 m29.7 m14.4 m8.1 m6.2 m

Current Assets

19.7 m17.5 m12.7 m44.3 m41.7 m31 m26.7 m23.8 m19.9 m

PP&E

29 k26 k34 k34 k31 k24 k76 k69 k59 k

Total Assets

20.5 m18 m13.3 m45.1 m42.4 m36.9 m32.6 m28.7 m20.6 m

Accounts Payable

725 k365 k651 k714 k647 k744 k760 k1.1 m980 k

Current Liabilities

1.2 m838 k1.1 m1.4 m1.3 m2.3 m1.7 m2.2 m2.5 m

Additional Paid-in Capital

99 m99.2 m99.5 m133.8 m134 m134.3 m134.5 m134.7 m134.9 m

Retained Earnings

(79.7 m)(82 m)(87.4 m)(90.1 m)(92.9 m)(99.7 m)(103.6 m)(108.3 m)(116.8 m)

Total Equity

43.8 m41.1 m34.6 m30.9 m26.5 m18 m

Financial Leverage

1 x1 x1.1 x1.1 x1.1 x1.1 x

Cash Flow

Annual

USDFY, 2016

Net Income

(16.4 m)

Depreciation and Amortization

24 k

Accounts Payable

841 k

Cash From Operating Activities

(15 m)

Purchases of PP&E

(12 k)

Cash From Investing Activities

(16.4 m)

Cash From Financing Activities

34 m

Interest Paid

4 k

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(4.8 m)(7.1 m)(2.7 m)(5.5 m)(8.3 m)(3.6 m)(7.5 m)(12.2 m)(4.3 m)

Depreciation and Amortization

5 k8 k4 k9 k14 k5 k9 k17 k7 k

Accounts Payable

128 k(232 k)(144 k)(198 k)(167 k)380 k391 k648 k(234 k)

Cash From Operating Activities

(5.5 m)(7.5 m)(3.1 m)(5.5 m)(7.9 m)(3.9 m)(7.4 m)(11.1 m)(4.3 m)

Purchases of PP&E

(5 k)(5 k)(2 k)(7 k)(9 k)(1 k)(2 k)(8 k)(1 k)

Cash From Investing Activities

(5 k)(5 k)(2 k)(7 k)(9 k)(5.2 m)(17 m)(19.6 m)3 m

Cash From Financing Activities

8.1 m8 m(55 k)34.3 m34.1 m(55 k)34.3 m34.1 m105 k

Interest Paid

2 k3 k1 k3 k4 k1 k3 k4 k

Ratios

Y, 2017

Financial Leverage

1.1 x